visiting our JustGiving page here.This means nine out of 10 patients with cystic fibrosis – more than 7,000 people – will now benefit from a therapy which tackles the underlying causes of the disease by helping the lungs work effectively.The landmark deal, negotiated ahead of a licence being granted by the European Medicines Agency, means that clinicians will be free to start prescribing the triple treatment to English patients as soon as the licence is finally granted, in the coming weeks.As many as 300 patients with rare mutations will also be able to benefit from the range of treatments produced by Vertex Pharmaceuticals.The deal is welcome news for patients with cystic fibrosis who have been advised to shield at home during the COVID-19.
Read more on manchestereveningnews.co.uk